SciVision Biotech Inc. (TPE:1786)
Taiwan · Delayed Price · Currency is TWD 79.80
+0.60 (0.76%)
Jan 22, 2026, 1:35 PM CST
SciVision Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 890.43 | 883.31 | 712.99 | 557.35 | 505.54 | 466.88 | Upgrade | |
Revenue Growth (YoY) | 7.11% | 23.89% | 27.93% | 10.25% | 8.28% | 6.63% | Upgrade |
Cost of Revenue | 251.88 | 227.63 | 200.49 | 185.48 | 163.7 | 123.6 | Upgrade |
Gross Profit | 638.55 | 655.68 | 512.49 | 371.87 | 341.84 | 343.28 | Upgrade |
Selling, General & Admin | 357.47 | 346.86 | 259.44 | 184.8 | 153.95 | 136.87 | Upgrade |
Research & Development | 80.86 | 60.71 | 53.42 | 52.46 | 65.94 | 59.78 | Upgrade |
Operating Expenses | 438.33 | 407.57 | 312.86 | 237.26 | 219.89 | 196.64 | Upgrade |
Operating Income | 200.22 | 248.11 | 199.64 | 134.61 | 121.94 | 146.64 | Upgrade |
Interest Expense | -6.26 | -5.67 | -8.22 | -6.46 | -8.07 | -7.47 | Upgrade |
Interest & Investment Income | 21.65 | 20.61 | 14.9 | 4.88 | 2.63 | 1.92 | Upgrade |
Currency Exchange Gain (Loss) | -23.9 | 20.48 | -0.51 | 11.81 | -1.46 | -2.26 | Upgrade |
Other Non Operating Income (Expenses) | -6.7 | 1.43 | 0.75 | 0.17 | 1.01 | 9.31 | Upgrade |
EBT Excluding Unusual Items | 185.01 | 284.96 | 206.56 | 145.02 | 116.05 | 148.13 | Upgrade |
Gain (Loss) on Sale of Investments | 6.45 | 6.45 | 2.9 | -1.98 | -0.13 | 4.36 | Upgrade |
Gain (Loss) on Sale of Assets | - | 0.19 | 0.54 | 30.55 | 0.13 | - | Upgrade |
Other Unusual Items | - | - | - | -0.04 | - | - | Upgrade |
Pretax Income | 191.46 | 291.6 | 210 | 173.55 | 116.06 | 152.49 | Upgrade |
Income Tax Expense | 26.74 | 49.34 | 32.1 | 31.83 | 14.34 | 24.48 | Upgrade |
Net Income | 164.72 | 242.25 | 177.9 | 141.72 | 101.72 | 128.01 | Upgrade |
Net Income to Common | 164.72 | 242.25 | 177.9 | 141.72 | 101.72 | 128.01 | Upgrade |
Net Income Growth | -23.75% | 36.17% | 25.53% | 39.32% | -20.53% | 6.05% | Upgrade |
Shares Outstanding (Basic) | 72 | 69 | 67 | 66 | 66 | 66 | Upgrade |
Shares Outstanding (Diluted) | 74 | 74 | 76 | 75 | 71 | 71 | Upgrade |
Shares Change (YoY) | -2.22% | -2.58% | 2.39% | 5.18% | 0.61% | 0.70% | Upgrade |
EPS (Basic) | 2.29 | 3.51 | 2.66 | 2.14 | 1.54 | 1.93 | Upgrade |
EPS (Diluted) | 2.24 | 3.30 | 2.41 | 1.92 | 1.51 | 1.89 | Upgrade |
EPS Growth | -23.43% | 37.15% | 25.26% | 27.30% | -20.11% | 5.88% | Upgrade |
Free Cash Flow | 145.99 | 235.11 | 257.28 | 167.03 | 72.73 | 59.63 | Upgrade |
Free Cash Flow Per Share | 1.98 | 3.16 | 3.37 | 2.24 | 1.02 | 0.84 | Upgrade |
Dividend Per Share | 3.250 | 3.250 | 2.500 | 2.000 | 1.420 | 0.885 | Upgrade |
Dividend Growth | 30.00% | 30.00% | 25.00% | 40.84% | 60.49% | -25.88% | Upgrade |
Gross Margin | 71.71% | 74.23% | 71.88% | 66.72% | 67.62% | 73.53% | Upgrade |
Operating Margin | 22.49% | 28.09% | 28.00% | 24.15% | 24.12% | 31.41% | Upgrade |
Profit Margin | 18.50% | 27.43% | 24.95% | 25.43% | 20.12% | 27.42% | Upgrade |
Free Cash Flow Margin | 16.39% | 26.62% | 36.08% | 29.97% | 14.39% | 12.77% | Upgrade |
EBITDA | 267.19 | 310.17 | 261.42 | 195.35 | 173.08 | 160.23 | Upgrade |
EBITDA Margin | 30.01% | 35.12% | 36.66% | 35.05% | 34.24% | 34.32% | Upgrade |
D&A For EBITDA | 66.97 | 62.06 | 61.78 | 60.74 | 51.14 | 13.59 | Upgrade |
EBIT | 200.22 | 248.11 | 199.64 | 134.61 | 121.94 | 146.64 | Upgrade |
EBIT Margin | 22.48% | 28.09% | 28.00% | 24.15% | 24.12% | 31.41% | Upgrade |
Effective Tax Rate | 13.96% | 16.92% | 15.29% | 18.34% | 12.35% | 16.06% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.